evipedia.ai ← Back to Review

Audit: QRS - Lactobacillus salivarius for Health & Longevity

Audit conducted on 03/08/2026 00:37 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 81
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All QRS content traces to the ER (Conclusion, Protocol, Benefits, Risks, Interactions, Monitoring).
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Speculative/low tiers and “early” framing mirror the ER’s cautious language.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No strengthening or softening detected.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications and Key Interactions both derive from the ER’s own section of that name.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 QRS carries no citations, PMIDs, or NCT identifiers.
1.6 The QRS does not introduce new attributions. 🟢 No new attributions introduced.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Tone matches the ER’s measured, evidence-graded voice.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Balanced expert-accessible tone throughout.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents evidence, not prescription.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 Content is presented as reference data, not advice.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Information-presenting register maintained.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No direct second-person address.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Plain language with necessary terms only.
2.8 Information is presented in a concise and very compact manner 🟢 Compact card/gate/table layout.
2.9 It DOES NOT address the reader directly 🟢 No “you”/”your” used.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing suits proactive health/longevity adults.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Protocol/monitoring detail assumes a willing audience.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not pitched to the general population.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Weighting reflects the target audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. 🟢 No “anti-aging” language present.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. 🟢 Clinical terminology used; At-A-Glance plain language is required by 7.4.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Table column headers in Monitoring (“Marker”, “Target”, “Why”). 🟢 All fixed labels/headings present and unmodified.
3.2 All “…” from the [qrs_template] are present in the QRS. 🟢 All expected variable spans present and coherent.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 No unaddressed spans altered.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No mapped ER section is empty.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Row/cell labels are consistent with the ER’s content and structure.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Functional protocol/time labels describe the actionable/temporal aspect faithfully.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji indicators; tiers conveyed via bold labels and CSS.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content condensed to a single-page budget.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment is first element after the doctype (lines 2–14).
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 YAML delimited by — (lines 3 and 13).
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; not rendered.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values trimmed; only duration quoted (contains colon).
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: lactobacillus_salivarius_2026-0803-0002_Opus_ER.md.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.7.02 matches the prompt version.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” 🟢 qrs_creation_date: 2026-0803-0030.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. 🟢 “Opus” is a single word.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 4.8.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier. 🟢 “Opus 4.8” is nickname + version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename matches the QRS filename.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 All values clean and consistent.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. 🟢 “Lactobacillus salivarius for Health & Longevity - Quick Reference Sheet”.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. 🟢 “Lactobacillus salivarius for Health & Longevity”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0803-0030 → 08/03/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 4.8”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header carries only the standard title and subline.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Distills the Conclusion faithfully.
7.2 [at_a_glance] is no longer than 60 words 🟢 52 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each clause maps to a Conclusion passage.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Plain-language (“a pregnancy infection”, “blood sugar”); no acronyms.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial citations.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No statistics present.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from the “Populations who should avoid or seek supervision” bullet.
8.2 [stop_items] represent the Contraindications from the ER 🟢 Six items match the ER contraindicated populations.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Each item is an <li>.
8.4 Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, or study details. No content after an em-dash, en-dash, or hyphen-dash. 🟢 Terse noun phrases; no trailing clauses.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible. 🟢 “(except specialized neonatal protocols)” preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation.
8.7 If no [stop_items] are present the section is left empty N/A stop_items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from the ER interaction bullets.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Antibiotics, immunosuppressants, mouth rinses; excludes the additive “other probiotics” and contraindicated populations.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Each item is an <li>.
9.4 Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, or study details. No content after an em-dash, en-dash, or hyphen-dash. 🟢 No trailing clauses; mitigation text stripped.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible. 🟢 Example drug lists preserved (e.g., “chlorhexidine”).
9.6 When the ER uses ranking notation inside parens that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation.
9.7 If no [caution_items] are present the section is left empty N/A caution_items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Derived from the Therapeutic Protocol section.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Dose, Timing, Frequency — the core actionable trio.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible. N/A Three actionable aspects are present.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All three cells populated with ER-derived content.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Breath odor, gum health, immune & gut effects.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Ordered High (breath) → Medium (gum) → Low (immune/gut).
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible. N/A Three time-to-effect aspects are present.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 All three sets populated from the ER.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Tiers mirror the ER Expected Benefits grades.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four tier variables populated.
12.3 Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. 🟢 Terse benefit names only.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 “(Halitosis)” and the “⚠️ Conflicted” flag dropped.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”. N/A All four sub-sections contain items.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Tiers mirror the ER risk grades.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four tier variables populated.
13.3 Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. 🟢 Terse risk names only.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No frequencies or study detail carried over.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”. N/A All four sub-sections contain items.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Derived from the Monitoring Protocol biomarker table.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All six quantitative markers present (organoleptic, VSC, calprotectin, hs-CRP, sIgA, HbA1c).
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Baseline + 4 weeks + 8–12 weeks + every 6–12 months.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Derived from the ER’s qualitative markers list.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All five qualitative markers present.

Issues 03/08/2026 00:37

Pass rate 100.00%. No issues found.